Related Experiment Videos

Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media

S D Oldroyd1, J L Haylor, S K Morcos

  • 1Sheffield Kidney Institute, Northern General Hospital, Sheffield, England.

Radiology
|September 1, 1995
PubMed
Abstract

Insights

Bosentan, an endothelin-receptor antagonist, protected rat kidneys from contrast media-induced damage in both isolated perfused kidney and conscious rat models. This suggests endothelin antagonists may prevent contrast-induced nephrotoxicity.

Area of Science:

  • Nephrology
  • Pharmacology
  • Renal Physiology

Background:

  • Contrast media administration can lead to contrast-induced nephrotoxicity.
  • Endothelin plays a role in regulating renal blood flow and function.

Purpose of the Study:

  • To investigate the protective effects of bosentan, an endothelin-receptor antagonist, against contrast media-induced renal injury.
  • To evaluate bosentan's efficacy in preventing nephrotoxicity in both an isolated perfused rat kidney model and a multiple-insult conscious rat model.

Main Methods:

  • Utilized an isolated perfused rat kidney (IPRK) model to assess renal function and blood flow.
  • Employed a multiple-insult model in conscious rats (unilateral nephrectomy, salt-free diet, indomethacin) to evaluate creatinine clearance after contrast media exposure.

Main Results:

  • In the IPRK, bosentan significantly inhibited the reduction in glomerular filtration rate and renal perfusate flow caused by contrast media (diatrizoate and iotrolan).
  • In conscious rats, bosentan markedly attenuated the decrease in creatinine clearance induced by diatrizoate exposure.

Conclusions:

  • Endothelin receptor antagonists, such as bosentan, demonstrate potential in mitigating contrast media-induced nephrotoxicity.
  • These findings suggest a therapeutic role for endothelin antagonists in preventing kidney damage associated with contrast media administration.

Related Concept Videos